Showing results (171-180 of 682) with videos related to
Sort By:
Pageof 69
Journal of Hematology & Oncology|July 27, 2023
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safetySrdan Verstovsek, Ruben A Mesa, Robert A Livingston, et al.Journal of Pediatric Hematology/Oncology|July 13, 2016
A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital AspleniaMaliha Khan, Cheng C Yin, Amber Yates, et al.Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.Cancer|November 27, 2004
New approaches in the treatment of myelofibrosisBryan T Hennessy, Deborah A Thomas, Francis J Giles, et al.Leukemia & Lymphoma|March 16, 2013
Significance of cytogenetic abnormalities in patients with polycythemia veraMatjaz Sever, Alfonso Quintás-Cardama, Sherry Pierce, et al.Blood|August 1, 2015
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosisMichael Deininger, Jerald Radich, Timothy C Burn, et al.Cancers|July 27, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and UpdateSiba El Hussein, Helen T Chifotides, Joseph D Khoury, et al.Annals of Hematology|June 29, 2018
The co-occurrence of driver mutations in chronic myeloproliferative neoplasmsPrajwal Boddu, Dai Chihara, Lucia Masarova, et al.Cancer Science|May 23, 2007
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406Jingxuan Pan, Alfonso Quintás-Cardama, Taghi Manshouri, et al.Leukemia Research|April 6, 2012
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisAlfonso Quintás-Cardama, Hagop Kantarjian, Zeev Estrov, et al.Pageof 69